// App-Quantinova.ai

1358 : Structure-based drug design of 3-site binding, high affinity inhibitors of S100B in malignant melanoma

Researchers

Presenter

  • Michael C. Cavalier

Principal Investigators

  • Paul T. Wilder

  • Diane Luci

  • David J. Maloney

  • Lei Fang

  • Mohd. Imran Ansari

  • Alexander D. MacKerell

  • Andrew Coop

  • Ajit Jadhav

  • David J. Weber

Medical Centers

  • University of Maryland, Balitimore County, Baltimore, MD.

  • National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • Advanced Glycosylation End-Product Specific Receptor

  • p53

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved